Found: 194
Select item for more details and to access through your institution.
Ruxolitinib dose management as a key to long-term treatment success.
- Published in:
- 2016
- By:
- Publication type:
- journal article
The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 6, p. 594, doi. 10.1002/ajh.25777
- By:
- Publication type:
- Article
Facing erythrocytosis: Results of an international physician survey.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 9, p. E225, doi. 10.1002/ajh.25545
- By:
- Publication type:
- Article
Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 11, p. E626, doi. 10.1002/ajh.24866
- By:
- Publication type:
- Article
Myeloproliferative neoplasm patient symptom burden and quality of life: Evidence of significant impairment compared to controls.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 10, p. 864, doi. 10.1002/ajh.24098
- By:
- Publication type:
- Article
Association of the blood eosinophil count with hematological malignancies and mortality.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 3, p. 225, doi. 10.1002/ajh.23916
- By:
- Publication type:
- Article
How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 6, p. 581, doi. 10.1002/ajh.23690
- By:
- Publication type:
- Article
A surprising cause of masses in the chest.
- Published in:
- American Journal of Hematology, 2013, v. 88, n. 6, p. 518, doi. 10.1002/ajh.23343
- By:
- Publication type:
- Article
Long-term outcome of pomalidomide therapy in myelofibrosis.
- Published in:
- American Journal of Hematology, 2012, v. 87, n. 1, p. 66, doi. 10.1002/ajh.22233
- By:
- Publication type:
- Article
International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.
- Published in:
- American Journal of Hematology, 2011, v. 86, n. 1, p. 96, doi. 10.1002/ajh.21892
- By:
- Publication type:
- Article
Loss of BRD4 induces cell senescence in HSC/HPCs by deregulating histone H3 clipping.
- Published in:
- EMBO Reports, 2023, v. 24, n. 10, p. 1, doi. 10.15252/embr.202357032
- By:
- Publication type:
- Article
The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis.
- Published in:
- Therapeutic Advances in Hematology, 2020, v. 11, p. 1, doi. 10.1177/2040620720925201
- By:
- Publication type:
- Article
Body Mass Index and Total Symptom Burden in Myeloproliferative Neoplasms Discovery of a U-shaped Association.
- Published in:
- Cancers, 2020, v. 12, n. 8, p. 2202, doi. 10.3390/cancers12082202
- By:
- Publication type:
- Article
Rare Cancers and Social Media: Analysis of Twitter Metrics in the First 2 Years of a Rare-Disease Community for Myeloproliferative Neoplasms on Social Media-#MPNSM.
- Published in:
- Current Hematologic Malignancy Reports, 2017, v. 12, n. 6, p. 598, doi. 10.1007/s11899-017-0421-y
- By:
- Publication type:
- Article
Approach to MPN Symptom Assessment.
- Published in:
- Current Hematologic Malignancy Reports, 2017, v. 12, n. 5, p. 381, doi. 10.1007/s11899-017-0399-5
- By:
- Publication type:
- Article
Social Media and Myeloproliferative Neoplasms (MPN): Analysis of Advanced Metrics From the First Year of a New Twitter Community: #MPNSM.
- Published in:
- Current Hematologic Malignancy Reports, 2016, v. 11, n. 6, p. 456, doi. 10.1007/s11899-016-0341-2
- By:
- Publication type:
- Article
Social Media and Myeloproliferative Neoplasms (MPN)-Focus on Twitter and the Development of a Disease-specific Community: #MPNSM.
- Published in:
- Current Hematologic Malignancy Reports, 2015, v. 10, n. 4, p. 413, doi. 10.1007/s11899-015-0287-9
- By:
- Publication type:
- Article
Quality of Life in MPN Comes of Age as a Therapeutic Target.
- Published in:
- Current Hematologic Malignancy Reports, 2014, v. 9, n. 4, p. 324, doi. 10.1007/s11899-014-0239-9
- By:
- Publication type:
- Article
The New Landscape of Therapy for Myelofibrosis.
- Published in:
- Current Hematologic Malignancy Reports, 2013, v. 8, n. 4, p. 325, doi. 10.1007/s11899-013-0178-x
- By:
- Publication type:
- Article
Transformation of a Chronic Myeloproliferative Neoplasm to Acute Myelogenous Leukemia: Does Anything Work?
- Published in:
- Current Hematologic Malignancy Reports, 2012, v. 7, n. 1, p. 78, doi. 10.1007/s11899-011-0107-9
- By:
- Publication type:
- Article
Myeloproliferative Neoplasms: Translating New Discoveries Into Better Outcomes, Better Quality of Life.
- Published in:
- Oncology (08909091), 2017, v. 31, n. 7, p. 521
- By:
- Publication type:
- Article
ATREVERSE A DECIR LA VERDAD DESDE EL BUEN CIUDADANO GRIEGO, AL RELATIVISMO DE NIETZSCHE Y EL CUIDADO DE SÍ EN FOUCAULT.
- Published in:
- Sophia, Colección de Filosofía de la Educación, 2022, n. 33, p. 199, doi. 10.17163/soph.n33.2022.07
- By:
- Publication type:
- Article
Surveys of food deserts and adherence to a Mediterranean diet among university students.
- Published in:
- Revista Nutrición Clínica y Dietética Hospitalaria, 2022, v. 42, n. 3, p. 97, doi. 10.12873/423duque
- By:
- Publication type:
- Article
Cross-Study Comparisons of JAK2 Inhibitors in Myelofibrosis: Risks and Recommendations.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 10, p. 714, doi. 10.1016/j.clml.2023.06.004
- By:
- Publication type:
- Article
MPN-343: The BET Inhibitor Pelabresib Decreases Inflammatory Cytokines, Improves Bone Marrow Fibrosis and Function, and Demonstrates Clinical Response Irrespective of Mutation Status in Myelofibrosis Patients in the Phase 2 MANIFEST Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S363, doi. 10.1016/S2152-2650(21)01835-8
- By:
- Publication type:
- Article
MPN-356: Transfusion Independence is Associated with Improved Overall Survival in Myelofibrosis Patients Receiving Momelotinib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S364, doi. 10.1016/S2152-2650(21)01836-X
- By:
- Publication type:
- Article
MPN-303: Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S360, doi. 10.1016/S2152-2650(21)01829-2
- By:
- Publication type:
- Article
MPN-164: Overall Survival (OS) and Progression-Free Survival (PFS) in Patients Treated with Fedratinib as First-Line Myelofibrosis (MF) Therapy and after Prior Ruxolitinib (RUX): Results from the JAKARTA and JAKARTA2 Trials.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S356, doi. 10.1016/S2152-2650(21)01822-X
- By:
- Publication type:
- Article
MPN-106: Improved Transfusion Independence Rates for Momelotinib vs Ruxolitinib in Anemic JAKi-Naïve Myelofibrosis Patients are Independent of Baseline Platelet or Transfusion Status.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S353, doi. 10.1016/S2152-2650(21)01817-6
- By:
- Publication type:
- Article
Poster: MPN-343: The BET Inhibitor Pelabresib Decreases Inflammatory Cytokines, Improves Bone Marrow Fibrosis and Function, and Demonstrates Clinical Response Irrespective of Mutation Status in Myelofibrosis Patients in the Phase 2 MANIFEST Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S235, doi. 10.1016/S2152-2650(21)01478-6
- By:
- Publication type:
- Article
Poster: MPN-356: Transfusion Independence is Associated with Improved Overall Survival in Myelofibrosis Patients Receiving Momelotinib.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S231, doi. 10.1016/S2152-2650(21)01456-7
- By:
- Publication type:
- Article
Poster: MPN-303: Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S231, doi. 10.1016/S2152-2650(21)01455-5
- By:
- Publication type:
- Article
Poster: MPN-164: Overall Survival (OS) and Progression-Free Survival (PFS) in Patients Treated with Fedratinib as First-Line Myelofibrosis (MF) Therapy and after Prior Ruxolitinib (RUX): Results from the JAKARTA and JAKARTA2 Trials.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S231, doi. 10.1016/S2152-2650(21)01454-3
- By:
- Publication type:
- Article
Poster: MPN-106: Improved Transfusion Independence Rates for Momelotinib vs Ruxolitinib in Anemic JAKi-Naïve Myelofibrosis Patients are Independent of Baseline Platelet or Transfusion Status.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S231, doi. 10.1016/S2152-2650(21)01453-1
- By:
- Publication type:
- Article
Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm (MPN)-Associated Intermediate- or High-Risk Myelofibrosis (MF) Resistant or Intolerant to Ruxolitinib: An Updated Analysis of the Phase II JAKARTA2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S356, doi. 10.1016/j.clml.2019.07.375
- By:
- Publication type:
- Article
Fedratinib Induces Spleen Responses and Reduces Symptom Burden as First-line or Salvage Therapy in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) and Low Platelet Counts.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S355, doi. 10.1016/j.clml.2019.07.374
- By:
- Publication type:
- Article
Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Models to Predict Response to JAK-inhibitor Therapy in Patients with Myelofibrosis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S358, doi. 10.1016/j.clml.2017.07.190
- By:
- Publication type:
- Article
Work Productivity Impairment and Symptom Burden among Patients with Myeloproliferative Neoplasms (MPNs): Findings from the Living with MPN Patient Survey.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S355, doi. 10.1016/j.clml.2017.07.184
- By:
- Publication type:
- Article
Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Update: a Novel Stratification of Myelofibrosis Patients by Likelihood of Response to JAK2 Inhibitors.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S95, doi. 10.1016/j.clml.2016.07.135
- By:
- Publication type:
- Article
Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Ruxolitinib for myelofibrosis--an update of its clinical effects.
- Published in:
- 2013
- By:
- Publication type:
- journal article